New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2013
08:30 EDTALXNAlexion weakness would be buying opportunity, says Deutsche Bank
Deutsche Bank believes any weakness in shares of Alexion from the company's FDA warning letter would be a buying opportunity. Deutsche thinks the letter will not be impactful to Soliris and points out the company has sufficient inventory on hand.
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
08:59 EDTALXNOn The Fly: Pre-Market Movers
Subscribe for More Information
06:43 EDTALXNAlexion raises 2014 adj EPS view to $4.75-$4.85 from $4.37-$4.47
Subscribe for More Information
06:41 EDTALXNAlexion reports Q1 adjusted EPS $1.16 ex-items, consensus $1.26
Subscribe for More Information
06:25 EDTALXNAlexion begins multinational registration trials of eculizumab
Alexion initiated a single, multinational, placebo-controlled trial to evaluate the safety and efficacy of eculizumab - Soliris - in patients with relapsing neuromyelitis optica, a life-threatening, ultra-rare neurologic disorder. Alexion also initiated a single, multinational, placebo-controlled trial in patients with refractory generalized myasthenia gravis, another rare and debilitating neurologic disorder. Currently, there are no approved treatments for NMO. Soliris is currently approved in the U.S., European Union, Japan and other countries for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Soliris is not approved in any country for the treatment of NMO or MG.
April 23, 2014
07:00 EDTALXNTerrapinn to hold a conference
Subscribe for More Information
06:37 EDTALXNAlexion's Soliris granted Orphan Drug Designation by European Commission
Subscribe for More Information
April 10, 2014
14:17 EDTALXNAlexion volatility elevated on wide price movement into Q1
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use